A Phase 3 Study to Evaluate the Glucose Response of G-Pen™ (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes

Trial Profile

A Phase 3 Study to Evaluate the Glucose Response of G-Pen™ (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors XERIS Pharmaceuticals
  • Most Recent Events

    • 15 Feb 2018 According to a Xeris Pharmaceuticals media release, data from this trial will be utilized to submit an NDA for our ready-to-use glucagon rescue pen for the treatment of severe hypoglycemia in late Q2 2018.
    • 15 Feb 2018 According to a Xeris Pharmaceuticals media release, the company shared the data with the FDA in a pre-NDA meeting and plans to present the complete results at a medical conference later this year.
    • 16 Oct 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top